An industry veteran reveals that payers, wanting to keep their patient members happy, are highly sensitive to public demand. Pharmaceutical companies can leverage this by generating significant patient and physician interest, which pressures payers into providing more favorable formulary coverage.

Many consumers believe that drugs purchased in the US work better than the same drugs in India. However, this is largely a psychological bias. Nearly half of the generic drugs sold in America are manufactured in India, subject to rigorous US regulatory norms, making the products functionally identical.

As doctors integrate AI into their work (e.g., ambient scribing), they expect more from their partners. MedTech sales reps can no longer rely solely on relationships; they must provide data-backed, highly personalized insights to be valuable.

The industry's historical success with large sales forces repeating messages to doctors created a deep-seated cultural mindset. This legacy of "pushing" information is a primary barrier to adopting a more human-centric, digitally native approach based on listening and responding to customer needs.

Pharmaceutical companies invest in creating high-quality, patient-centric educational documents. However, these resources often fail to reach patients because physicians are hesitant to distribute materials bearing a corporate logo, creating a "last-mile" delivery problem for crucial information.

Modern physician segmentation in the pharmaceutical industry has moved far beyond potential and product adoption. Leading US companies now use up to 79 parameters—including beliefs, motivators, and barriers—to build complex personas. This enables hyper-personalized engagement strategies tailored to each physician's unique context.

Contrary to the popular narrative, China doesn't dominate the final API market against India. Instead, China's strategy is to supply low-cost chemical intermediates. Indian firms then perform the final, more complex and profitable conversion steps to create the finished Active Pharmaceutical Ingredient (API).

Telehealth platforms built on selling generic drugs face margin compression from price wars and high customer acquisition costs. Partnering to offer branded, in-demand medications provides a competitive advantage, creating a "gravitational pull" that attracts patients and builds a more defensible business model.

India produces 60% of the world's drugs by volume but captures only 2-5% of the revenue. This disparity exists because it dominates the post-patent generic market, where prices can fall by over 95%, while innovator companies capture the high-margin monopoly period.